FDA Approves Revuforj® (revumenib) in Adult & Pediatric Patients with R/R NPM1 Mutated AML October 29, 2025
Initial clinical data on the combination of AB8939 + venetoclax in the first three patients with R/R AML announced October 15, 2025
Pivotal Ziftomenib Data in R/R NPM1-Mutated AML Published in the Journal of Clinical Oncology September 30, 2025
Revuforj® (revumenib) Included in NCCN Guidelines for the Treatment of R/R NPM1 Mutated AML September 23, 2025
CHARM Therapeutics raises $80M in Series B financing to advance development of menin inhibitor for AML September 3, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
Enrollment Open for 160 mg Dosing Cohort of Tuspetinib in Ph 1/2 TUSCANY Trial of 1L Triple Drug Therapy in induction-ineligible AML patients August 12, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Approval of the third of four stages of the Ph 1/2 study of AB8939 in R/R AML patients announced August 5, 2025
Positive Data from Long-Term Follow-Up Analysis of the Ph 3 AGILE Trial of TIBSOVO® (ivosidenib) in IDH1-mutated AML Announced July 29, 2025
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML July 23, 2025
All Primary Endpoints Met in Ph 2 Trial of SLS009 in R/R AML; FDA Guidance Received to Advance into 1L Therapy Study July 23, 2025
Supplemental NDA for INQOVI (decitabine & cedazuridine) + venetoclax for 1L AML adults ineligible for intensive induction chemo accepted by FDA July 15, 2025
